Introduction: Tirzepatide peptides give a dual GIP and GLP-1 receptor agonist motion with a 5-working day fifty percent-life enabling after-weekly dosing and excellent fat reduction efficacy in medical trials. In many weightloss journeys, issues usually compound: discovering a good treatment with manageable dosing frequency, ensuring accessibility